These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 25261231)

  • 1. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
    Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
    Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
    Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
    Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
    Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
    Shao L; Zhang B; He C; Lin B; Song Z; Lou G; Yu X; Zhang Y
    Chin Med J (Engl); 2014; 127(2):266-71. PubMed ID: 24438614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
    Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
    Li X; Yang XJ; Sun YF; Qin N; Lü JL; Wu YH; Zhang H; Zhang Q; Zhang SC
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):627-31. PubMed ID: 23159001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
    Biaoxue R; Hua L; Wenlong G; Shuanying Y
    Oncotarget; 2016 Dec; 7(52):86902-86913. PubMed ID: 27893423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
    Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
    Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
    Wang HP; Zhang L; Wang YX; Tan FL; Xia Y; Ren GJ; Hu P; Jiang J; Wang MZ; Xiao Y
    Chin Med J (Engl); 2011 Jul; 124(13):1933. PubMed ID: 22088449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
    Liu D; Zhang L; Wu Y; Jiang J; Tan F; Wang Y; Liu Y; Hu P
    Lung Cancer; 2015 Sep; 89(3):262-7. PubMed ID: 26162563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
    Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
    Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
    Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
    Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
    Hu X; Zhang L; Shi Y; Zhou C; Liu X; Wang D; Song Y; Li Q; Feng J; Qin S; Xv N; Zhou J; Zhang L; Hu C; Zhang S; Luo R; Wang J; Tan F; Wang Y; Ding L; Sun Y
    PLoS One; 2015; 10(11):e0142500. PubMed ID: 26599904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
    Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
    Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.